kabutan

Cuorips Inc.(4894) Summary

4894
TSE Growth
Cuorips Inc.
6,670
JPY
-110
(-1.62%)
Apr 30, 12:54 pm JST
41.57
USD
Apr 29, 11:54 pm EDT
Result
PTS
outside of trading hours
6,661
Apr 30, 12:58 pm JST
Summary Chart Historical News Financial Result
PER
PBR
11.2
Yield
ー%
Margin Trading Ratio
306.76
Stock Price
Apr 30, 2026
Opening Apr 30, 9:00 am
6,730 JPY 42.00 USD
Previous Close Apr 28
6,780 JPY 42.58 USD
High Apr 30, 9:00 am
6,730 JPY 42.03 USD
Low Apr 30, 9:32 am
6,610 JPY 41.26 USD
Volume
35,300
Trading Value
0.24B JPY 1.47M USD
VWAP
6678.44 JPY 41.63 USD
Minimum Trading Value
667,000 JPY 4,157 USD
Market Cap
0.06T JPY 0.34B USD
Number of Trades
163
Liquidity & Number of Trades
As of Apr 30, 2026
Liquidity
Slightly High
1-Year Average
780
1-Year High Feb 20, 2026
16,829
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 100 744,000 7440.00
Apr 17, 2026 0 741,100
Apr 10, 2026 0 749,700
Apr 3, 2026 0 777,400
Mar 27, 2026 0 768,900
Company Profile
Cuorips Inc. specializes in the development and commercialization of iPS cell-derived cardiomyocyte sheets.
Sector
Pharmaceuticals
Cuorips Inc. focuses on the development and commercialization of human iPS cell-derived cardiomyocyte sheets, working towards the practical application of regenerative medicine products. Through collaborative research with Osaka University and partnerships with major pharmaceutical companies, Cuorips has established advanced cell cultivation techniques. The company's products are expected to improve cardiac function and aid recovery from heart failure in patients with severe cardiac conditions. Utilizing its proprietary commercial cell culture and processing facility "CLiC-1", Cuorips also engages in Contract Development and Manufacturing Organization (CDMO) services and cell culture supernatant businesses. The CDMO services include development support and contract manufacturing, providing various cells as raw materials. The cell culture supernatant business effectively utilizes the liquid byproduct from the cell cultivation process. Cuorips aims to realize a wide range of regenerative medicine technologies, including the development of new catheter-based treatments and research on in vivo regeneration factor inducers.